| Tonya Johannes, ARNP | |
|
1229 C Ave E, Oskaloosa, IA 52577-4246 | |
| (641) 672-3360 | |
| Not Available |
| Full Name | Tonya Johannes |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 1229 C Ave E, Oskaloosa, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205292448 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | A122183 (Iowa) | Primary |
| Entity Name | Mahaska County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639159304 PECOS PAC ID: 2769388677 Enrollment ID: O20041202000965 |
News Archive
Low doses of natural Hi-maize resistant starch could improve insulin sensitivity in men at risk for prediabetes, according to a study underwritten by National Starch LLC, a business unit of Corn Products International. The American Diabetes Association defines prediabetes as a non-disease state where blood sugar (glucose) levels are higher than normal, but not yet high enough to be diagnosed as diabetes.
H2O Audio (www.h2oaudio.com), the leader in high performance sweatproof and waterproof headphones and accessories for active people everywhere, today unveiled three progressive new products.
Two studies conducted 20 years apart in England reveal an apparent increase in healthy ageing, or years lived healthily, reflecting less cognitive impairment; and an increase in the proportion of life lived healthily, through a larger proportion of years lived with disability but less rather than more severe disability.
The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.
A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tonya Johannes, ARNP 1229 C Ave E, Oskaloosa, IA 52577-4246 Ph: (641) 672-3360 | Tonya Johannes, ARNP 1229 C Ave E, Oskaloosa, IA 52577-4246 Ph: (641) 672-3360 |
News Archive
Low doses of natural Hi-maize resistant starch could improve insulin sensitivity in men at risk for prediabetes, according to a study underwritten by National Starch LLC, a business unit of Corn Products International. The American Diabetes Association defines prediabetes as a non-disease state where blood sugar (glucose) levels are higher than normal, but not yet high enough to be diagnosed as diabetes.
H2O Audio (www.h2oaudio.com), the leader in high performance sweatproof and waterproof headphones and accessories for active people everywhere, today unveiled three progressive new products.
Two studies conducted 20 years apart in England reveal an apparent increase in healthy ageing, or years lived healthily, reflecting less cognitive impairment; and an increase in the proportion of life lived healthily, through a larger proportion of years lived with disability but less rather than more severe disability.
The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.
A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.
› Verified 3 days ago
Stefanie Yearian, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3259 Fax: 641-672-3259 | |
Christine Beaird, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3100 | |
Mrs. Christine Lorraine Doyle, ARNP, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1417 A Ave E, Suite 100, Oskaloosa, IA 52577 Phone: 641-673-7537 Fax: 641-673-5235 | |
Mrs. Joyce Elaine Prough, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3159 | |
Danielle Rice, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 410 N 12th St, Oskaloosa, IA 52577 Phone: 641-672-3360 | |
Arthur Zacharjasz, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1229 C Ave E, Oskaloosa, Ia 52577, Oskaloosa, IA 52577 Phone: 641-672-3100 |